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Editorial on the Research Topic
Cellular Therapies: Past, Present and Future
This collection of review articles on hematopoietic stem cell transplantation (HSCT) has been
compiled by enthusiastic post-graduate students within the Marie Curie Initial Training Network
CELLEUROPE. It starts with two reviews of current research with a historical perspective and focus
on either animal or human HSCT studies.
Boieri et al. summarize the importance of early animal experiments from the 1950’s including
graft-vs.-host disease (GvHD) a major complication of HSCT, initially termed “runt disease.”
The article focuses on the contribution of animal experiments to the understanding of the
pathophysiology of acute and chronic GvHD and the development of therapies to overcome these
complications. It ends with a discussion of general advantages and limitations of animal models for
studying GvHD.
The historic milestones of HSCT in man are reviewed by Juric et al. They describe the
development of conditioning therapies enabling engraftment of HSC. The pivotal role of human
leukocyte antigen (HLA) typing technologies for the introduction and continuous improvement
of HSCT is explained. The shift from serological to molecular methods is discussed in view of
their importance for the utilization of matched unrelated donors. Further parameters affecting
HSCT outcome are introduced focusing on stem cell sources ranging from bone marrow to
peripheral HSC and cord blood. The article closes with an outlook on new developments, such
as the adoptive transfer of T cells engineered to express chimeric antigen receptors (CARs) directed
against antigens present on leukemic cells.
Ghimire et al. discuss in detail the pathophysiology of GvHD explaining initiation and course
of both the acute and chronic forms and introducing new strategies to limit these complications.
Despite these efforts, especially chronic GvHD remains a major challenge that warrants further
research.
The risk to elicit GvHD by transplantation of allogeneic T cells is balanced by their potential
for profound graft-vs.-leukemia (GvL) effects, giving rise to curative therapies for malignancies.
Dickinson et al. summarize clinical observations and experimental results demonstrating that
allogeneic T cells in the graft reduce the risk of relapse of malignancy after HSCT. They describe the
development of donor lymphocyte infusion (DLI) as a means to treat relapse. In addition, newer
strategies are explained including the infusion of allogeneic mismatched natural killer (NK) cells or
tumor antigen-specific T cells.
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The reconstitution of the immune system after HSCT is
reviewed by Ogonek et al.. It is of the utmost importance for the
success of HSCT, that the various immune cell subsets recover
and regain function in a timely manner. Neutrophils are the
first cells that usually reappear within the first month after the
conditioning therapy. They are followed in the first 3 months
by NK cells and then by T cells. B cell recovery takes longer
and may need up to 2 years post-HSCT. The reconstitution of
regulatory T cells is explained focusing on factors which influence
reconstitution, such as immunosuppressive treatment. Finally,
the reconstitution of virus-specific T cells is reviewed in view of
the clinical importance of these cells for avoiding complications
such as CMV reactivation.
Biomarkers have gained much attention as they may predict
the occurrence of GvHD and allow for risk-adapted treatment.
Juric et al. review the recent developments and start with a
discussion of cellular biomarkers, such as CD19+CD21low B
cells that are promising in predicting chronic GvHD. Besides
cells, serum molecules have been reported to predict GvHD.
In addition to proteins, miRNAs are potentially promising
biomarkers for GvHD. Moreover, recent developments to
identify biomarkers in urine by proteomic approaches are
presented. Juric et al. close by discussing the challenge to validate
and integrate the great variety of biomarkers that have been
suggested during the last few years.
Gam et al. discuss the genetic associations of HSCT
outcome focusing on non-histocompatibility genes and three
specific examples. Firstly, it is discussed how polymorphisms
of FOXP3 and FOXP3-regulating microRNAs affect the risk of
GvHD. The miR-155 and miR-146a regulatory network, their
polymorphisms and role after HSCT is outlined as a second
example. Polymorphisms of the MICA gene, which encodes a
ligand of the activating NK cell receptor NKG2D, are introduced
as a third example. Furthermore, mRNA and miRNA expression
profiling studies aiming at the identification of HSCT associated
risks are summarized. The review ends with a discussion of the
few genome wide association studies, which have been performed
so far to elucidate the role mainly of non-HLA polymorphisms in
controlling the outcome of HSCT.
The final review by Reis et al. outlines recent developments in
cellular immunotherapies for HSCT-associated complications.
These include the transfer of mesenchymal stromal cells
(MSCs) or MSC-derived extracellular vesicles to treat
GvHD. Further complications are infections occurring in
the immunocompromised patients. In recent years, strategies
to employ anti-virus-specific T cells in the therapy of
viral infections have been developed. Relapse is another
outcome that can be targeted by cellular immunotherapies,
e.g., with CAR T cells and in this chapter the challenges
of these new and fascinating therapeutic strategies is
discussed.
This collection of articles is dedicated to Professor
Bent Rolstad (1947-2016), an enthusiastic and committed
supervisor of two of the project’s post-graduate students and
Professor Jon van Rood (1926-2017), who was encouraging
and supportive to the students in writing and revising the
articles.
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